Your AI-Trained Oncology Knowledge Connection!
Kathleen N. Moore, MD, associate director for clinical research, gynecologic oncologist at The Stephenson Cancer Center, The University of Oklahoma, explores the impact of the SOLO-1 trial in the field of ovarian cancer, in particular, the benefits olaparib provides and the light it shines on the importance of using genetic testing to inform treatment decisions.
Adverse events decreased among patients with high-risk ovarian cancer who received a 200- or 300-mg individualized starting dose of niraparib, based upon baseline bodyweight and platelet count, compared with a 300-mg fixed starting dose.
Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, suggesting that repeat use could become more common.
Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the effect of age on the efficacy of rucaparib (Rubraca) in patients with recurrent ovarian carcinoma.
Patients with recurrent ovarian cancer who received niraparib maintenance therapy experienced more progression-free time without experiencing symptoms or toxicity compared with placebo; the benefit was 4-fold for those with germline (g) BRCA-mutated disease and 2-fold for non-gBRCA-mutated ovarian cancer.
First-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.
Currently approved PARP inhibitors have demonstrated similar efficacy in the setting of maintenance therapy for patients with ovarian cancer but differ with respect to the type and frequency of grade 3/4 adverse events, results of a network meta-analysis suggested.
Combination therapy with the PARP inhibitor olaparib and the PD-L1 inhibitor durvalumab induced objective responses in more than 70% of patients with relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.
Brian M. Slomovitz, MD, gynecologic oncologist, Sylvester Comprehensive Cancer Center, University of Miami, discusses GOG 3007, a randomized phase II study of everolimus (Afinitor) and letrozole or hormonal therapy (medroxyprogesterone acetate/tamoxifen) in women with advanced, persistent or recurrent endometrial carcinoma during the 2018 Society of Gynecologic Oncology Annual Meeting.
Jaron Mark, MD, gynecologic oncology fellow, Roswell Park Comprehensive Cancer Center, discusses the implementation of an ultra-restrictive opioid prescription protocol (UROPP) in patients undergoing major gynecologic surgery, which radically decreased dispensed opioids without reducing pain control, during the 2018 Society of Gynecologic Oncology Annual Meeting.
Patients with platinum-resistant/refractory ovarian cancer had durable responses with the combination of the PARP inhibitor niraparib (Zejula) and pembrolizumab (Keytruda).
Almost half of patients with platinum-resistant ovarian cancer had objective responses to combination therapy with pembrolizumab plus the antifolate antibody-drug conjugate mirvetuximab soravtansine.
Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
Patients with HER2-positive uterine serous carcinoma had a greater than 50% improvement in progression-free survival when treated with trastuzumab and chemotherapy versus chemotherapy alone, a small randomized trial showed.
Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.
To access the value of the maintenance therapies and biomarkers to direct treatment for patients with platinum-sensitive recurrent ovarian cancer, investigators used ASCO’s Net Health Benefit and ESMO’s Magnitude of Clinical Benefit Scale.
Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.
Baseline body weight and platelet counts were early predictors for future AE-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Implementation of an "ultra-restrictive" opioid prescription protocol for gynecologic surgery led to an 89% reduction in the number of opioid tablets dispensed at discharge and a high rate of patient satisfaction.
Bradley J. Monk, MD, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses how to decide which PARP inhibitor to use when treating a patient with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
The use of immune checkpoint inhibitors in women with recurrent ovarian cancer has a clinical benefit but a higher rate of adverse events than previously reported in other tumor types.
An immunotherapy targeting HPV-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer.
Maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy did not improve overall survival rates in women with ovarian cancer who had achieved complete remission.
Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer.
Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.
Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma.
Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with BRCA-proficient ovarian cancer.
Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.
The PARP inhibitor niraparib improved progression-free survival in patients with recurrent, platinum-sensitive, high-grade ovarian cancer, regardless of BRCA status, according to a review of the phase III ENGOT-OV16/NOVA trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting.
Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
